Source comparison
Stacking Thymosin Alpha-1 VIP Long COVID Research: Comparison
Thymosin Alpha-1 + VIP Stack Dual targeting: thymopoiesis restoration + neuroinflammation suppression via TLR modulation and VPAC receptor signalling 40-55% clinical response rate; fatigue reduction 6.2/11 points; cognitive improvement 3.4 MOCA points Injectio
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1 + VIP Stack
- Dual targeting: thymopoiesis restoration + neuroinflammation suppression via TLR modulation and VPAC receptor signalling
- 40-55% clinical response rate; fatigue reduction 6.2/11 points; cognitive improvement 3.4 MOCA points
- Injection site reactions (18%), transient nasal irritation (22%), headache (12%)
- Phase II data (n=62-118); no Phase III completion
- Strongest mechanistic rationale for addressing both immune exhaustion and CNS inflammation; limited large-scale validation
- Low-Dose Naltrexone (LDN)
- Opioid receptor antagonism → endorphin upregulation; proposed microglial modulation
- 30-38% clinical response; fatigue reduction 3.8/11 points
- Insomnia (15%), vivid dreams (20%), GI upset (10%)
- Multiple small RCTs (n=30-80 each); meta-analysis pending
- Widely accessible; modest effect size; mechanism less specific to Long COVID pathology
- Paxlovid (Nirmatrelvir/Ritonavir)
- Viral protease inhibition; proposed effect on residual viral reservoirs
- Symptom improvement in 20-25% when initiated within 90 days post-infection; minimal benefit beyond 90 days
- Dysgeusia (40%), diarrhoea (8%), drug interactions (varies)
- Phase III data in acute COVID; observational data only for Long COVID
- Best evidence in early post-acute phase; limited utility for established Long COVID beyond 3 months
- Intravenous Immunoglobulin (IVIG)
- Passive antibody transfer; immune modulation via Fc receptor binding
- Variable (15-45% response); higher in autoantibody-positive subsets
- Infusion reactions (12%), headache (25%), thrombotic events (rare, <2%)
- Case series and small open-label trials; no RCTs
- High cost; response heterogeneity suggests patient selection critical; lacks standardised dosing protocol
- Metformin
- AMPK activation → mitochondrial biogenesis; proposed anti-inflammatory effects
- 18-22% clinical response in observational cohorts; preventive data stronger than treatment data
- GI upset (20-30%), lactic acidosis (rare)
- One Phase III prevention trial (COVID-OUT); treatment data observational only
- Modest effect; better evidence for prevention when started during acute infection